The precise spatio-temporal dynamics of protein activity are often critical in determining cell behaviour, yet for most proteins they remain poorly understood; it remains difficult to manipulate protein activity at precise times and places within living cells. Protein activity has been controlled by light, through protein derivatization with photocleavable moieties 1 or using photoreactive small-molecule ligands 2 . However, this requires use of toxic ultraviolet wavelengths, activation is irreversible, and/or cell loading is accomplished via disruption of the cell membrane (for example, through microinjection). Here we have developed a new approach to produce genetically encoded photoactivatable derivatives of Rac1, a key GTPase regulating actin cytoskeletal dynamics in metazoan cells 3, 4 . Rac1 mutants were fused to the photoreactive LOV (light oxygen voltage) domain from phototropin 5, 6 , sterically blocking Rac1 interactions until irradiation unwound a helix linking LOV to Rac1. Photoactivatable Rac1 (PA-Rac1) could be reversibly and repeatedly activated using 458-or 473-nm light to generate precisely localized cell protrusions and ruffling. Localized Rac activation or inactivation was sufficient to produce cell motility and control the direction of cell movement. Myosin was involved in Rac control of directionality but not in Rac-induced protrusion, whereas PAK was required for Racinduced protrusion. PA-Rac1 was used to elucidate Rac regulation of RhoA in cell motility. Rac and Rho coordinate cytoskeletal behaviours with seconds and submicrometre precision 7, 8 . Their mutual regulation remains controversial 9 , with data indicating that Rac inhibits and/or activates Rho 10, 11 . Rac was shown to inhibit RhoA in mouse embryonic fibroblasts, with inhibition modulated at protrusions and ruffles. A PA-Rac crystal structure and modelling revealed LOV-Rac interactions that will facilitate extension of this photoactivation approach to other proteins.
Recent NMR studies revealed the mechanism of a protein light switch in Avena sativa phototropin1 (refs 6, 12) : a flavin-binding LOV2 domain interacts with a carboxy-terminal helical extension (Ja) in the dark. Photon absorption leads to formation of a covalent bond between Cys 450 and the flavin chromophore, causing conformational changes that result in dissociation and unwinding of the Ja helix. We fused the complete LOV2-Ja sequence (404-547) to the amino terminus of a constitutively active Rac1, anticipating that the LOV domain in its closed conformation would block the binding of effectors to Rac1, and that light-induced unwinding of the Ja helix would release steric inhibition, leading to Rac1 activation ( Fig. 1a ). Sampling of different junctional sequences in pull-down assays revealed that connecting Leu 546 of LOV2-Ja to Ile 4 of Rac1 led to substantial reduction in Rac1 binding to its effector PAK ( Fig. 1b and Supplementary Fig. 1a ). To ensure that the photoactivatable Rac1 would induce no dominant-negative effects and that its activity would not be subject to upstream regulation, mutations were introduced to abolish GTP hydrolysis and diminish interactions with nucleotide exchange factors, guanine nucleotide dissociation inhibitors (Q61L) and GTPase activating proteins (E91H and N92H) ( Supplementary  Fig. 2 and Supplementary text 'Characterization of Rac1 constructs'). This resulted in the photoactivatable analogue of Rac1 (PA-Rac1) used in the following studies. Pull-down assays showed that PA-Rac1 has greatly reduced affinity for its effector protein PAK in the dark, as does a PA-Rac1 construct containing a light-insensitive LOV2 mutation (C450A) 13 . Effector binding was restored in a PA-Rac1 construct containing a LOV2 mutant (I539E) 14 which mimics the unfolded 'lit state' ( Fig. 1b and Supplementary Fig. 1b ). Isothermal titration experiments indicated that the dark and lit state mutants of PA-Rac1 differed tenfold in effector binding (200 nM versus 2 mM) ( Supplementary Fig. 3 and Supplementary Table 1) , with lit state effector affinity similar to that of native Rac 15 .
Activation of PA-Rac1 was examined in HeLa cells expressing a YFP fusion of PA-Rac1 to gauge expression level. The cells remained quiescent when illuminated with wavelengths longer than flavin absorbance (515, 568 or 633 nm, data not shown), but within seconds after switching to 458 nm, lamellipodial protrusions and membrane ruffles appeared around the cell edges ( Fig. 1c and Supplementary Movie 1). To show that this effect was due to PA-Rac1, kymograms were used to quantify maximum protrusion length; irradiation of PA-Rac1 elicited protrusions that were four times as long as those seen in cells expressing either LOV domain alone or the light-insensitive PA-Rac1(C450A) mutant ( Supplementary Fig. 4 ). An important advantage of PA-Rac1 is its ability to control precisely the subcellular location of Rac activation. We first examined this in mouse embryo fibroblasts (MEFs) stably expressing PA-Rac1, and cultured without serum to minimize cell activity before irradiation. Irradiation of 20-mm spots at the cell edge generated large protrusions clearly localized next to the point of irradiation ( Fig. 1d and Supplementary Movie 2). Repeated irradiation led first to ruffles and then to protrusion. YFP-actin, YFP-PAK and YFP-Arp3 revealed actin polymerization at the edge of the Racinduced protrusions with associated translocation of downstream effectors, and induction of localized PAK phosphorylation was shown by immunostaining ( Supplementary Figs 5 and 6 and Supplementary Movies 3 and 4). Movement of a laser spot to different positions led to cessation of ruffling or protrusion at the initial irradiation position and new activities appearing where the laser spot was brought to rest (HeLa cells, Supplementary Movie 5), demonstrating reversible activation. In MEF cells, more prone to movement than HeLa cells, complex shape changes were produced by 'painting' the cell with the laser spot (Supplementary Movie 6). The area of protrusions in MEF cells was dependent on light dosage, indicating the valuable ability to control the level of Rac1 activation ( Supplementary Fig. 7 ). PA-Rac1 diffusion was analysed using fluorescence recovery after photobleaching (FRAP) and using PA-Rac1 tagged with photoactivatable GFP 16 , indicating that PA-Rac1 diffuses more slowly than cytosolic proteins, probably because it is membrane bound (10 mm spot, FRAP D 5 0.55 mm 2 s 21 or t 1/2 5 12.1 s; PA-GFP t 1/2 5 14.6 s). The half-life of dark recovery for PA-Rac1 was determined to be 43 s at room temperature. Simulation using this value indicated that, for two adjacent 10-mm spots, the unirradiated spot will achieve at most 7.5% the activation of the irradiated region ( Supplementary Fig. 8c ). Together these studies validate PA-Rac1 as a robust, genetically encoded and reversible caged protein effective in living cells. We used PA-Rac1 to ask whether localized Rac activation is sufficient to specify cell polarity. In MEF cells, activating Rac1 at one spot near the cell edge not only generated protrusion locally, but also produced retraction on the opposite side of the cell ( Fig. 2a and Supplementary Movie 9). To test whether this cross-cell coordination was due to a gradient of Rac1 activity, we fused the LOV domain to a dominant-negative mutant of Rac1 using the same linkage as in PA-Rac1. Irradiation of this PA-Rac1(T17N) led to nearby retraction rather than protrusion, and now generated protrusion in other areas of the cell ( Fig. 2a and Supplementary Movies 10 and 11). The ability of Rac1 alone to control polarized movement was confirmed by repeated irradiation at the cell edge, which could be used to produce prolonged cell movement by generating consistent coordinated extension and retraction (MEF cells, Fig. 2b and Supplementary Movie 12; HEK293 cells, Supplementary Movie 13). In contrast to MEF and HEK293 cells, HeLa cells showed localized protrusion but could not be induced to retract or move simply by activating Rac (Supplementary Movie 3) , indicating that Rac-induced motility is subject to modulation by other pathways.
(Supplementary
PA-Rac1 enabled control of Rac1 activity without the prior cellular compensation seen with other techniques, that is, mutation or altered expression. Using this advantage, we examined the role of myosin, a key mediator of actin-based contractility, in Rac-induced motility. Global inhibition of myosin activity using the myosin ATPase inhibitor blebbistatin or the myosin light chain kinase inhibitor ML-7 strongly affected Rac's ability to specify the direction of cell movement, but minimally affected Rac-induced protrusion (Fig. 2c, d ). Myosin may mediate Rac's control of directionality through induction of tail retraction 17 , contraction of the cell cortex to direct protrusive force 18 , or coupling of actin to adhesions differently at the front and rear 19 . In contrast, inhibition of PAK was found to strongly affect Rac-induced protrusion ( Supplementary Fig. 9 ). Inhibition of the Rho-activated kinase ROCK using Y27632 suggested a role for ROCK in Rac-induced protrusion, but these results must be interpreted with caution owing to known off-target effects 20 .
Where and how Rac regulates Rho in vivo remains largely unknown; this was examined by using PA-Rac1 together with a RhoA biosensor 8 . Localized activation of Rac1 led to immediate inhibition of RhoA, and this inhibition spread outwards from the irradiated spot ( Fig. 3a and Supplementary Movie 14). This was not simply an artefact of biosensor photobleaching, as irradiating the photoinactive C450M mutant ( biosensor photobleaching and recovery, but no prolonged local inhibition or wave of inhibition ( Fig. 3a ). There were marked differences between constitutive MEF protrusions and protrusions induced by pulsed PA-Rac1 irradiation. In contrast to constitutive protrusions, RhoA activity was greatly reduced in protrusions induced by PA-Rac (Fig. 3b ). Inhibition of RhoA seems to be compartmentalized or controlled kinetically when Rac is activated in the context of normal motility, as both active Rac and active Rho are seen at the leading edge 7, 8, 21 . PA-Rac activation led to large ruffles moving from the site of irradiation rearwards towards the nucleus ( Supplementary Movie 15 ), suggesting that Rac regulates rearwards membrane flow. In control experiments, irradiation of cells expressing the photoinactive C450M mutant did not produce polarized ruffling or show reduced RhoA activity (data not shown).
To understand the structural basis of the PA-Rac1 switch for future application to other proteins, we performed Rosetta structure prediction simulations 22 on several LOV2-Rac1 constructs, and determined high-resolution crystal structures of photoactive and inactive PA-Rac1 in the dark state. The crystal structures confirmed that the LOV domain occludes effector binding in the dark state ( Fig. 4a and Supplementary Table 2 ). LOV-Ja adopted a closed conformation that superimposes with the recently published structure of isolated LOV-Ja (ref. 23 ). In the conformational ensemble predicted by simulations of the dark state, the effector binding site of Rac was sterically blocked by the LOV domain in a majority of the low-energy models ( Supplementary Tables 3-5 and Supplementary Figs 10-13 ). Consistent with pull-down assays ( Fig. 1b and Supplementary  Fig. 1a ), adding or removing even one residue from the connection between LOV and Rac resulted in conformational ensembles with exposed effector binding sites. In the dark state, Rac was seen to form an extensive interface with the LOV domain ( Fig. 4b) , occluding Rac binding interactions. Given the substantial structural similarity between Rac1 and Cdc42, we hypothesized that the LOV domain could also be used to cage Cdc42. However, the linkage used for PA-Rac1 failed to reduce Cdc42 binding to PAK ( Fig. 4c and Supplementary Fig. 1d ). Using the PA-Rac1 crystal structure as a template, a model was built of the Cdc42-LOV dark state. At the interface between Rac and LOV a hydrophobic cluster is formed between residues Phe 37 and Trp 56 from Rac and Leu 422, Pro 423, Ile 428, Tyr 508 and Leu 546 from LOV. Consistent with this being a weak, non-evolved interaction, most of the hydrogenbonding potential at the Rac-LOV interface is satisfied by buried and partially buried water molecules instead of inter-domain hydrogen bonds (Fig. 4b ). This interface model was used to identify a mutation to Cdc42, F56W, at the Rac-LOV interface, that was predicted to stabilize the dark state. Pull-down assays showed that this mutation substantially improves dark-state inhibition of PAK binding, and produces differential affinity for Cdc42 effector in the dark versus the lit state ( Fig. 4d ). In living cells, irradiation of the mutated PA-Cdc42 led to production of filopodia and in some cases protrusions and/or ruffles, consistent with Cdc42 induction of filopodia and activation of Rac 24 ( Supplementary Fig. 14 and Supplementary  Movie 16 ). These results argue that PA-Rac1 can serve as a blueprint for engineering other caged GTPases.
We have engineered genetically encoded photoactivatable Rac1 analogues that enable precise spatial and temporal control of Rac activity in live cells, with reversible activation at 458 or 473 nm. Localized Rac activation or deactivation was sufficient to generate polarized cell movement. Rac could be activated without cellular compensation, enabling us to probe the role of myosin and PAK in Rac-mediated motility. Spatially regulated Rac inhibition of Rho was demonstrated in living cells. Structural studies indicate that a nonevolved interaction at the Rac-LOV interface can be engineered to cage other GTPases. This study and other recent work [25] [26] [27] [28] show that coupling genetically encoded light-modulated domains to other proteins provides a versatile new route to control protein activities in living cells.
METHODS SUMMARY
Imaging experiments were conducted on an Olympus FluoView 1000 laser scanning confocal microscope and an Olympus IX81-ZDC inverted microscope. Biosensor imaging was performed as previously described 8, 29 . Simultaneous biosensor imaging and activation of PA-Rac was achieved using a MAG Biosystems FRAP-3D add-on (Photometrics) for galvanometer control of laser position. 
METHODS
DNA cloning. The cDNA encoding the LOV2 domain of Avena sativa (oat) Phototropin1 (404-546), including the C-terminal helical extension (Ja), was a gift from K. Moffat. Chimaeric fusion constructs consisting of LOV2-Ja fused to Rac1 or Cdc42 were generated using an overlapping PCR approach so that precise junctional sequences could be engineered without being limited by restriction sites. These included truncations/extensions of the LOV2-Ja C terminus (539-547), the N terminus (2-4) of the GTPases, or insertions of designed Schellman caps (KEAGADQI and KELKEAGADQI) 1 . The QuickChange (Stratagene) protocol was used to introduce additional point mutations, including C450A or C450M, and I539E to mimic the dark and lit state of the LOV domain, respectively. PA-Rac1 was constructed as follows: LOV2-Ja(404-546)-Rac1(4-192)/Q61L/E91H/N92H. These constructs were inserted into a pTriEx (Novagen) vector for transient expression in mammalian cells as well as in bacteria. For crystallization, C-terminally truncated PA-Rac1 (D181-192) was subcloned into the pQE-30 vector (Qiagen). Fluorescent proteins mVenus 2 , mCherry 3 and mPA-GFP 4 were inserted at the N terminus of the LOV domain with a short GSGS linker to monitor expression and subcellular localization. After initial characterization, PA-Rac1 with different fluorescent protein tags was subcloned into pBabe-TetCMV vector for retroviral production and establishment of stable MEF Tet-Off cell lines. High-fidelity Pfu Turbo DNA polymerase (Stratagene) was used in PCR reactions and all plasmids were verified by DNA sequencing.
Pull-down assay of effector binding. mVenus-tagged LOV2-Ja and Rac1 fusion constructs were coexpressed with Flag-tagged PAK1 in HEK293 (LinXE) cells by transient transfection using Fugene 6 (Roche). The cells were lysed in 50 mM Tris pH 7.5, 150 mM NaCl and 1% Triton X-100 (lysis buffer) with addition of EDTA-free protease inhibitor cocktail (Roche). After brief centrifugation, the supernatants were incubated with Flag/M2-agarose (Sigma) followed by washes with lysis buffer, and elution with lysis buffer containing 200 mg ml 21 33Flag peptide (Sigma). All procedures were done at 4 uC under red light, facilitated using Handee spin columns (Pierce). The purified protein complexes as well as cell lysates were fractionated on 4-12% NuPAGE gels Fractions containing the protein were concentrated (30 kDa cutoff, Millipore) and further purified by Superose 6 gel filtration chromatography (GE Healthcare, 10 mM Tris pH 8.5, 20 mM NaCl, 5 mM MgCl 2 and 2 mM DTE). Before crystallization the protein was concentrated to 10 mg ml 21 (30 kDa cutoff, Millipore). All proteins were characterized spectroscopically. PA-Rac1 showed reversible light/dark conversion. The dark recovery rate of PA-Rac1 was measured as described previously 5 . The inactive C450A mutation showed no effect on light illumination whereas truncated C450M (D181-192) was prone to aggregation on light illumination and, therefore, no data for light/dark conversion could be measured. Crystallization. Crystallization was carried out under dimmed red light at 20 uC. PA-Rac1 and its C450A and C450M mutants were crystallized using the vapour diffusion method by mixing equal volumes of protein (10 mg ml 21 ) and precipitant solution (100 mM calcium acetate/100 mM sodium cacodylate/12% (w/v) PEG 8000 or 4% (w/v) PEG 4000/100 mM potassium chloride). Yellow pencilshaped crystals appeared overnight and grew to a final size of 50 3 50 3 1,000 mm 3 in a week. To avoid photoactivation, crystal handling was done by shielding the microscope light bulb with a 2-mm-thick RG630 filter (ITOS). Before cooling the crystals in liquid nitrogen they were transferred stepwise to precipitant solution supplemented with 20% (v/v) ethylene glycol for cryoprotection. Data collection and structure determination. Diffraction data were collected at the X10SA beamline (Swiss Light Source) under standard cryogenic settings. Data were reduced using the XDS suite 6 ( Supplementary Table 2 ) and the structure was solved by molecular replacement 7 using subsequentially 2V0U 8 and 1MH1 9 as the initial models. During several rounds of refinement with PHENIX 10 and manual model building in COOT 11 , FMN, GTP, Mg 21 , Ca 21 and solvent molecules were included in the model. Structures were validated using MOLPROBITY 12 and PROCHECK 13 (see Supplementary Table 2 for final statistics). Structural modelling for linker optimization. The Rosetta program 14, 15 was used to predict the dark state structure of LOV2-Rac1 based on the solved crystal structures of dark state LOV2 8 (Protein Data Bank (PDB) code 2V0U) and Rac1 9 (PDB code 1MH1). Structure prediction simulations were performed on LOV2-Rac1 545-4, 546-4 and 547-4 constructs. In these simulations, the torsion angles of the residues connecting the two proteins were optimized with Monte Carlo sampling. Using the Rosetta domain assembly protocol 16 , we first applied 1,000 W and Y backbone torsion angle movements of up to 180u each to three residues connecting LOV2 to Rac1 in a low-resolution representation. Small backbone torsion angle moves of up to 4u were then performed on a high-resolution representation of LOV2-Rac1, followed by a global repacking of all side-chain rotamers. After every 15 cycles of small moves and repacking, further repacking was restricted to the rotamers at the interface and next to the LOV2-Rac1 linkers. This sequence of refinement was repeated for a total of 150 cycles. Next, we adopted a series of small moves, global rotamer repacking, as well as backbone minimization within 5 residues of the LOV2-Rac1 linker for high-resolution optimization cycles. After every ten cycles, only rotamers at the interface and next to the LOV2-Rac1 linkers were repacked. A total of 100 such high resolution optimizations were used to generate models, which were further scored using Rosetta's energy function. One-thousand models, each representing a different folding trajectory, were generated per construct from simulations using the domain assembly protocol. The complex structure of Rac3 and the CRIB domain of PAK4 (PDB code 2OV2) was used to model the interaction of CRIB-containing effectors with LOV2-Rac1 constructs. The crystal structure of Rac1 9 (PDB 1MH1) was superimposed onto the complex structure by mapping the Ca atoms of Rac1 onto those of Rac3. This derived complex structure was then superimposed onto the LOV2-Rac1 models to create model-CRIB complexes. Side-chain rotamers at the interface of each complex were optimized using rotamer repacking 17 . These complexes were scored using the Rosetta energy function. A low-scoring model-CRIB complex indicated the model could bind CRIB, whereas a high-scoring model-CRIB complex indicated clashes between atoms of the model and the CRIB domain, resulting in reduced binding.
Models generated in a simulation were grouped into clusters according to their pairwise root mean square deviation (r.m.s.d.). The r.m.s.d. (in Å ) of the Ca atom positions of each model from all other models in the simulation was calculated. Those models falling within a radius of 3 Å r.m.s.d. from each other were grouped into a cluster. A cluster member representing the centre of each cluster was chosen. Isothermal titration calorimetry. Dark and lit state mimetics of PA-Rac1, C450A and I539E were cloned into a pTriEx vector with an N-terminal six histidine tag. Residues 65-150 of PAK1, comprising the extended CRIB domain, were cloned into a pET23 vector, with a C-terminal 6xhistidine tag. All proteins were expressed in E. coli strain BL21(DE3) cells (Stratagene) at 16 uC overnight in the dark. Cells were lysed in 50 mM sodium phosphate pH 7.0, 300 mM NaCl and 5 mM MgCl 2 . Proteins were purified under yellow light using TALON Metal Affinity Resin (Clontech) and eluted with 150 mM imidazole at pH 7.0. The proteins were dialysed against 50 mM sodium phosphate, 150 mM NaCl, 7.15 mM 2-mercaptoethanol, 5 mM MgCl 2 and 1% glycerol. Protein concentrations were quantified based on the estimated molar extinction coefficients (280 nm) of the corresponding polypeptides or the reported molar extinction coefficient (447 nm) of LOV2-FMN, and were confirmed with SDS-PAGE followed by Coomassie staining. ITC experiments were performed by injecting the dark state mutant C450A of PA-Rac1 (0.14 mM) or the lit state mutant I539E (0.13 mM) into the CRIB domain of PAK1 (10 mM) using a Microcal VP-ITC calorimeter at 25uC. Each titration consisted of 29 injections of 10 ml of mutants of PA-Rac1. The baseline of each titration was determined and subtracted from all of the data points. Titration data for the heat change per injection were fitted to a one-site binding model using Origin software (OriginLab). Cell culture. HeLa, HEK293 (ATCC) and parental MEF/3T3 Tet-Off cells (Clontech) were maintained in DMEM containing 10% FBS following the supplier's culturing instructions. Stable MEF lines were passaged with addition of 1 ng ml 21 doxycycline, sufficient to suppress protein expression under the Tet-CMV promoter. Doxycycline was removed 24 h before live cell imaging. It was important to control expression level because small amounts of Rac activity from PA-Rac were apparently present before irradiation, as evidenced by increased ruffling at high expression levels. This was probably due to the equilibrium amount of active Rac present in the dark state. For constructs tagged with fluorescent proteins, expression level could be roughly approximated as proportional to brightness/unit area, enabling use of cells with similar expression.
